Multimodality strategy for cardiovascular risk assessment: Performance in 2 population-based cohorts

Circulation

Volumn 135, Issue 22, 2017, Pages 2119-2132

  De Lemos, James A ^a   Ayers, Colby R ^a   Levine, Benjamin ^a,b,c   DeFilippi, Christopher R ^d   Wang, Thomas J ^e   Hundley, W Gregory ^f   Berry, Jarett D ^a   Seliger, Stephen L ^g   McGuire, Darren K ^a   Ouyang, Pamela ^h   Drazner, Mark H ^a   Budoff, Matthew ⁱ   Greenland, Philip ^j   Ballantyne, Christie M ^k   Khera, Amit ^a  

^a University Medical Center   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Institute for Exercise and Environmental Medicine   (United States)

^d INOVA HEART AND VASCULAR INSTITUTE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

biomarker; C reactive protein; coronary calcium; NT proBNP; risk prediction; troponin T

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN T; BIOLOGICAL MARKER;

ADULT; AGATSTON SCORE; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; CREATININE BLOOD LEVEL; ELECTROCARDIOGRAM; ELECTRON BEAM TOMOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OUTCOME ASSESSMENT; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; BLOOD; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; ETHNIC GROUP; ETHNOLOGY; HEALTH SURVEY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROSPECTIVE STUDY; TEXAS;

ADULT; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMBINED MODALITY THERAPY; ELECTROCARDIOGRAPHY; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; TEXAS;

EID: 85018859001     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.027272     Document Type: Article

References (57)

1. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 129 25 Suppl 2 S49 S73. doi: 10.1161/01.cir.0000437741.48606.98.
2. Ridker PM, Cook NR, Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013 382 1762 1765. doi: 10.1016/S0140-6736(13)62388-0.
3. Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM, Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA 2014 311 1406 1415. doi: 10.1001/jama.2014.2630.
4. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ, American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011 123 933 944. doi: 10.1161/CIR.0b013e31820a55f5.
5. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ, Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014 129 837 847. doi: 10.1161/CIRCULATIONAHA.113.005119.
6. Miller JD, Aronis KN, Chrispin J, Patil KD, Marine JE, Martin SS, Blaha MJ, Blumenthal RS, Calkins H, Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. J Am Coll Cardiol 2015 66 2899 2906. doi: 10.1016/j.jacc.2015.10.047.
7. deFilippi CR, de Lemos JA, Tkaczuk AT, Christenson RH, Carnethon MR, Siscovick DS, Gottdiener JS, Seliger SL, Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults. J Am Coll Cardiol 2012 60 2539 2547. doi: 10.1016/j.jacc.2012.08.1006.
8. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT, A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015 373 2103 2116
9. Ridker PM, Hennekens CH, Buring JE, Rifai N, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000 342 836 843. doi: 10.1056/NEJM200003233421202.
10. Ridker PM, Stampfer MJ, Rifai N, Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001 285 2481 2485
11. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA, Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008 358 1336 1345. doi: 10.1056/NEJMoa072100.
12. Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, Dragano N, Grönemeyer D, Seibel R, Kälsch H, Bröcker-Preuss M, Mann K, Siegrist J, Jöckel KH, Heinz Nixdorf Recall Study Investigative Group Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010 56 1397 1406. doi: 10.1016/j.jacc.2010.06.030.
13. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, Greenland P, Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010 303 1610 1616. doi: 10.1001/jama.2010.461.
14. Everett BM, Berger JS, Manson JE, Ridker PM, Cook NR, B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. J Am Coll Cardiol 2014 64 1789 1797. doi: 10.1016/j.jacc.2014.04.089.
15. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS, Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004 350 655 663. doi: 10.1056/NEJMoa031994.
16. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J, B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009 120 2177 2187. doi: 10.1161/CIRCULATIONAHA.109.884866.
17. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM, Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011 123 1367 1376. doi: 10.1161/CIRCULATIONAHA.110.005264.
18. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK, Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010 304 2503 2512. doi: 10.1001/jama.2010.1768.
19. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL, Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010 304 2494 2502. doi: 10.1001/jama.2010.1708.
20. Everett BM, Cook NR, Magnone MC, Bobadilla M, Kim E, Rifai N, Ridker PM, Pradhan AD, Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. Circulation 2011 123 2811 2818. doi: 10.1161/CIRCULATIONAHA.110.009928.
21. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet 2010 375 132 140
22. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010 122 e584 e636. doi: 10.1161/CIR.0b013e3182051b4c.
23. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS, Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006 355 2631 2639. doi: 10.1056/NEJMoa055373.
24. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J, Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008 358 2107 2116. doi: 10.1056/NEJMoa0707064.
25. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engström G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ, Wang TJ, Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009 302 49 57. doi: 10.1001/jama.2009.943.
26. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altshuler DM, Newton-Cheh C, Orho-Melander M, Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008 358 1240 1249. doi: 10.1056/NEJMoa0706728.
27. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, Kuulasmaa K, Yarnell J, Schnabel RB, Wild PS, Münzel TF, Lackner KJ, Tiret L, Evans A, Salomaa V, MORGAM Project Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010 121 2388 2397. doi: 10.1161/CIRCULATIONAHA.109.901413.
28. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, Ho JE, Fradley MG, Ghorbani A, Xanthakis V, Kempf T, Benjamin EJ, Levy D, Vasan RS, Januzzi JL, Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012 126 1596 1604. doi: 10.1161/CIRCULATIONAHA.112.129437.
29. Wang TJ, Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011 123 551 565. doi: 10.1161/CIRCULATIONAHA.109.912568.
30. Kannel WB, Abbott RD, A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study. Am Heart J 1986 111 391 397
31. Desai CS, Ning H, Lloyd-Jones DM, Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: the Atherosclerosis Risk in Communities Study. Heart 2012 98 330 334. doi: 10.1136/heartjnl-2011-300819.
32. Chrispin J, Jain A, Soliman EZ, Guallar E, Alonso A, Heckbert SR, Bluemke DA, Lima JA, Nazarian S, Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2014 63 2007 2013. doi: 10.1016/j.jacc.2014.01.066.
33. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP, Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 2002 156 871 881
34. Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, Basit M, Cooper RS, Iannacchione VG, Visscher WA, Staab JM, Hobbs HH, Dallas Heart Study Investigators The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004 93 1473 1480. doi: 10.1016/j.amjcard.2004.02.058.
35. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto Jde P, Morrow DA, de Lemos JA, Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004 44 1812 1818. doi: 10.1016/j.jacc.2004.07.047.
36. Sokolow M, Lyon TP, The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949 37 161 186
37. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC, Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 2005 234 35 43. doi: 10.1148/radiol.2341040439.
38. Jain T, Peshock R, McGuire DK, Willett D, Yu Z, Yu Z, Vega GL, Guerra R, Hobbs HH, Grundy SM, Dallas Heart Study Investigators African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol 2004 44 1011 1017. doi: 10.1016/j.jacc.2004.05.069.
39. de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH, Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J 2009 157 746 753. doi: 10.1016/j.ahj.2008.12.017.
40. Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB Jr, Herrington DM, Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 2006 152 593 598. doi: 10.1016/j.ahj.2006.02.015.
41. Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, Wians FH Jr, Grundy SM, McGuire DK, Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006 113 38 43. doi: 10.1161/CIRCULATIONAHA.105.575241.
42. Ndumele CE, Matsushita K, Sang Y, Lazo M, Agarwal SK, Nambi V, Deswal A, Blumenthal RS, Ballantyne CM, Coresh J, Selvin E, N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2016 133 631 638. doi: 10.1161/CIRCULATIONAHA.115.017298.
43. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA, Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010 56 254 261. doi: 10.1373/clinchem.2009.132654.
44. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F, Centers for Disease Control and Prevention; American Heart Association Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003 107 499 511
45. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, Wilson PW, Kritchevsky SB, Health ABC Study Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 2008 1 125 133. doi: 10.1161/CIRCHEARTFAILURE.108.768457.
46. Agarwal SK, Chambless LE, Ballantyne CM, Astor B, Bertoni AG, Chang PP, Folsom AR, He M, Hoogeveen RC, Ni H, Quibrera PM, Rosamond WD, Russell SD, Shahar E, Heiss G, Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) study. Circ Heart Fail 2012 5 422 429. doi: 10.1161/CIRCHEARTFAILURE.111.964841.
47. Chambless LE, Cummiskey CP, Cui G, Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med 2011 30 22 38. doi: 10.1002/sim.4026.
48. Pencina MJ, D'Agostino RB, Steyerberg EW, Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011 30 11 21. doi: 10.1002/sim.4085.
49. Kremers WK, Technical report series no. 80, concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time 2007 Rochester, MN Mayo Clinic College of Medicine
50. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 129 25 Suppl 2 S1 S45. doi: 10.1161/01.cir.0000437738.63853.7a.
51. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS, Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010 362 2155 2165. doi: 10.1056/NEJMoa0908610.
52. Nambi V, Liu X, Chambless LE, de Lemos JA, Virani SS, Agarwal S, Boerwinkle E, Hoogeveen RC, Aguilar D, Astor BC, Srinivas PR, Deswal A, Mosley TH, Coresh J, Folsom AR, Heiss G, Ballantyne CM, Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk-the atherosclerosis risk in communities study. Clin Chem 2013 59 1802 1810. doi: 10.1373/clinchem.2013.203638.
53. Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X, Daviglus ML, Lloyd-Jones DM, Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol 2013 61 1510 1517. doi: 10.1016/j.jacc.2013.01.022.
54. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB, General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008 117 743 753. doi: 10.1161/CIRCULATIONAHA.107.699579.
55. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL, Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011 4 313 320. doi: 10.1161/CIRCOUTCOMES.110.958165.
56. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720.
57. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K, Natriuretic peptide-based screening and collaborative care for heart failure: the stop-hf randomized trial. JAMA 2013 310 66 74